HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones despite ongoing going-concern risks.

HCW Biologics shares soared Friday after the company reported stronger quarterly results, advanced a key licensing deal and reaffirmed upcoming autoimmune clinical data milestones…

HCW Biologics (HCWB) reports Q1 EPS of $0.37 and $6.54M in sales. Find out why the stock skyrocketed and what's next.